AtriCure’s AtriClip Pro-Mini Device Used in First Procedure After FDA Clearance

April 14, 2025—AtriCure, Inc. recently announced the first use of the AtriClip Pro-Mini left atrial appendage (LAA) exclusion system for minimally invasive concomitant procedures. The AtriClip Pro-Mini device, which received FDA 510(k) clearance earlier this year, builds upon AtriCure’s AtriClip platform of implanted surgical LAA devices, noted the company.

According to AtriCure, the new AtriClip Pro-Mini is preloaded with a surgical LAA management implant 60% smaller than the next-lowest profile AtriClip device. The size reduction provides enhanced visualization for precise and secure exclusion of the LAA during minimally invasive procedures, stated the company.

“The AtriClip Pro-Mini device immediately impressed me with its significantly smaller profile,” commented Ahmed Romeya, MD, in AtriCure’s press release. “It maintained the parallel closure and uniform pressure necessary for effective LAA exclusion.”

Dr. Romeya, who is a cardiovascular surgeon at Midwest Heart and Vascular Specialists in Overland Park, Kansas, continued, “The enhanced visualization offered by the AtriClip Pro-Mini device will undoubtedly increase surgeon confidence during these procedures.”